Association between genetic variation in the ABCB1 gene and switching, discontinuation, and dosage of antidepressant therapy: Results from the rotterdam study

Journal of Clinical Psychopharmacology

Volumn 33, Issue 4, 2013, Pages 546-550

  Noordam, Raymond ^a   Aarts, Nikkie ^a   Hofman, Albert ^a,b   Van Schaik, Ron H N ^a   Stricker, Bruno H ^a,b,c   Visser, Loes E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Netherlands Consortium for Healthy Ageing   (Netherlands)

^c Inspectorate of Health Care   (Netherlands)

Author keywords

ABCB1; adverse drug reaction; antidepressive agents; drug intolerance

Indexed keywords

ANTIDEPRESSANT AGENT; MULTIDRUG RESISTANCE PROTEIN 1; PAROXETINE;

AGED; ARTICLE; COHORT ANALYSIS; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG SUBSTITUTION; FEMALE; HAPLOTYPES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LOGISTIC MODELS; MALE; NETHERLANDS; ODDS RATIO; P-GLYCOPROTEIN; PHENOTYPE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879843945     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318291c07b     Document Type: Article

References (18)

1. Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther. 2009;124(1):57-73.
2. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75(1):13-33.
3. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473-3478.
4. Moons T, de Roo M, Claes S, et al. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics. 2011;12(8):1193-1211.
5. Gow JM, Hodges LM, Chinn LW, et al. Substrate-dependent effects of human ABCB1 coding polymorphisms. J Pharmacol Exp Ther. 2008;325(2):435-442.
6. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315(5811):525- 528.
7. Salama NN, Yang Z, Bui T, et al. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci. 2006;95(10): 2293-2308.
8. Kato M, Fukuda T, Serretti A, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):398-404.
9. Sarginson JE, Lazzeroni LC, Ryan HS, et al. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics. 2010;20(8):467-475.
10. De Luca V, Mundo E, Trakalo J, et al. Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania. Pharmacogenomics J. 2003;3(5):297-299.
11. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57(2):203-209.
12. Hofman A, van Duijn CM, Franco OH, et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol. 2011;26(8):657-686.
13. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2012. Oslo:World Health Organization (WHO) ATC/DDD Index; 2011. Available at: http://www.whocc.no/atc-ddd-index/.
14. Aarnoudse AJ, Dieleman JP, Visser LE, et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics. 2008;18(4):299-305.
15. Perroud N, Bondolfi G, Uher R, et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics. 2011;12(3):365-377.
16. Roberts RL, Joyce PR, Mulder RT, et al. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2002;2(3):191-196.
17. Jensen BP, Roberts RL, Vyas R, et al. Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers. Br J Clin Pharmacol. 2012;73(4):619-628.
18. Lin KM, Chiu YF, Tsai IJ, et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics. 2011;21(4):163-170.